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ABSTRACT 
 
P16 and MGMT hypermethylation predicts surgical outcomes  
in curative resected mid/distal bile duct cancer. 
 
 
Joon Seong Park  
 
Department of Medicine  
The Graduate School, Yonsei University  
 
(Directed by Professor Dong Sup Yoon) 
 
Extrahepatic bile duct cancer is a primary malignancy arising from 
epithelium of extrahepatic biliary tract. In patients with extrahepatic bile duct 
carcinoma, the 5-year survival rate was 38.3%; a very poor prognosis has 
been reported. In these patients, the important prognostic factors include the 
TNM stage, cell differentiation and histologic type. Nevertheless, we often 
encounter a substantial number of patients whose prognosis is not consistent 
with the TNM stage. Therefore, other prognostic criteria are mandatory than 
the TNM staging system which has been widely used at present. We aimed to 
evaluate the potential role of DNA promoter methylation of gene involved in a 
variety of celluar function including adhesion (CDH1), cell division (p16) and 
survival (DAPK), to predict disease free survival (DFS) and overall survival 
(OS) in curative resected mid/distal bile duct cancer.   
Sixty-five mid/distal bile duct carcinoma specimens obtained at Severance 
G
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Hospital of Yonsei University College of Medicine from January 2000 to 
December 2006. Methylation of interest loci was confirmed using 
pyrosequecning. 
The significant methylation frequencies (MtI > 5%) of the 3 gene analyzed 
were 17% for P16, 54% for DAPK, 60% for E-cadherin. P16 and DAPK MtI 
status correlated with perineural invasion and tumor depth, respectively. In 65 
patients, the 3-year and 5-year overall survival was 54.9% and 48.4%, 
respectively. In multivariate analysis of overall survival, presence of lymph 
node metastasis and P16 methylation status were identified as an independent 
prognostic factors for overall survival. In patient with unmethylated of P16, 
the 3- and 6-yeat survival rates were 60.8 % and 54.9 %, respectively. In 
patients with a hypermethylated of P16, the 3- and 6-yeat survival rates were 
27.3 % and 0.0 %, respectively.   
P16  hypermethylation can predict overall survival in curative resected mid/distal 
bile duct cancer. Classification of mid/distal bile duct cancer by both genetic and 
epigenetic profiles may improve the capability of predicting prognosis and of 
applying tailored therapy in mid/distal cancer.  
 
 
 
-------------------------------------------------------------------------------------- 
Key words : Bile duct cancer, Surgical outcomes, Hypermethylation,  
Pyroswquencing, P16InK4a 
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I. INTRODUCTION 
Extrahepatic bile duct cancer is a primary malignancy arising from 
epithelium of extrahepatic biliary tract. Extrahepatic bile duct (EBD) 
carcinoma is rare malignant tumors, with a frequency of 1 per 100,000 people 
per year in the United state,1 whereas the prevalence of EBD carcinoma in 
Korea is more frequent than that of the Western countries.2 In patients with 
EBD carcinoma, the 5-year survival rate was 38.3%; a very poor prognosis 
has been reported.3 In these patients, the important prognostic factors include 
the TNM stage, cell differentiation and histologic type.3  Nevertheless, we 
often encounter a substantial number of patients whose prognosis is not 
consistent with the TNM stage. Therefore, other prognostic criteria are 
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mandatory than the TNM staging system which has been widely used at 
present.  
DNA methylation refers to the addition of a methyl group to one of the four 
bases that constitute the coding sequence of DNA.4,5 Aberrant methylation in 
tumor suppressor gene associated with poor prognosis.6 DNA methylation is 
used as a clinical biomarker in hematopoietic malignancies and colon 
cancer,6,7 however, the potential of DNA methylation as prognostic factors is 
only now beginning to be explored in bile duct cancer. 
We reviewed the results of published studies looking at molecular 
biomarkers and their prognostic significance in bile duct cancer to select 
molecular markers. The PubMed was searched using the following keywords 
in varying combinations in order to identify published works in English 
language to December 2010: bile duct cancer, prognosis, biomarkers and 
molecular markers. Individual biomarkers were also included in these 
searches. Gallbladder cancer, Klatskin tumor, intrahepatic 
cholangiocarcinoma were excluded from survey.  
In this study, we evaluated the potential role of DNA promoter methylation 
of gene involved in a variety of celluar function including adhesion (CDH1), 
cell division (p16) and survival (DAPK), to predict disease free survival 
(DFS) and overall survival (OS) in curative resected mid/distal bile duct 
cancer.   
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II. MATERIALS AND METHODS 
Patients and clinical assessment  
Sixty-five mid/distal bile duct carcinoma specimens obtained at Severance 
Hospital of Yonsei University College of Medicine from January 2000 to 
December 2006. This study was approved by the Institutional Review Board 
of Gangnam Severance Hospital. Clinical data were established from chart 
review. Follow up included radiographic imaging with histological 
verification of recurrence. Time to recurrence (TTR) and overall survival (OS) 
were measured in months from the date of diagnosis to the time of disease 
progression or death.  
 
DNA extraction from Formalin-fixed Paraffin Embedded (FFPE) Tissue  
We extracted DNA from archival FFPE samples following manual 
microdissection of 5-μm thick H-E stained sections into neoplastic 
compartments, containing at least 80% tumor cells. The microdissected tissue 
fragments were transferred into a microcentrifuge tube and incubated in 1.5 
ml of xylene for 60 min. After centrifugation at 14,000 rpm for 3 min, the 
supernatant was removed. This step was repeated once. Subsequently, the 
tissue samples were washed in 1 ml of 99% ethanol. After centrifugation at 
7200 rpm for 3 min the supernatant was discharged. The washing procedure 
was repeated five times. The samples were air dried at ambient temperature 
for 30 min. DNA was extracted using QiaAmp DNA Micro kit (Qiagen, 
G
G
]G
Valencia, CA, USA) according to the manufacturer's instructions. The eluted 
DNA samples were stored at -20ଇ 
 
Sodium Bisulfite modification.  
Bisulfite modified gDNA was prepared using EZ DNA Methylation-Gold kit 
(Zymo Research, USA) according to the manufacturer’s instructions. The 
bisulfite reaction was carried out on 1μg gDNA and the reaction volume was 
adjusted to 20μl with sterile water and 130μl of CT conversion Reagent were 
added. The sample tubes were placed in a thermal cycler (MJ Research) and 
performed the following steps : 10min at 98ଇ, 2hours 30min at 64ଇ, and 
stored at 4୅.  
The DNA was purified using reagent contained in EZ DNA 
Methylation-Gold kit (Zymo Research, USA). The converted samples were 
added into Zymo-Spin ICTM Column containing 600μl of the M-Binding 
Buffer and mixed by inverting the column several times. The column was 
centrifuged at full speed for 30sec and discarded the flow-through. The 
column was washed by adding 200μl of M-Wash Buffer and spined at full 
speed and then 200μl of M-Desulphonation Buffer was added to the column 
and let stand at room temperature (20-30୅) for 15-20min. After incubation, 
the column was centrifuged at full speed for 30sec. The column was washed 
by adding 200μl of M-Wash Buffer and spined at full speed (repeat this step).     
G
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The converted gDNA was eluted by adding 20-50μl of M-Elution Buffer 
into the column and spin. DNA samples were finally stored at -20ଇ until 
further use. 
 
Pyrosequencing analysis. 
We used the bisulfite pyrosequenicng method for methylation analyses of 
three genes, p16, CDH1, DAPK1, Each primer was designed using PSQ assay 
design program (Biotage, USA). The primer sequence was listed in the Table 
1. 
PCR reaction was carried out in a volume of 20μl with 50ng or more 
converted gDNA, PCR premixture (Bioneer, Korea), 2μl of 10pmole/μl 
Primer-S, and 2μl of 10pmole/μl biotinylated-Primer-As. The amplification 
was carried out according to the general guidelines suggested by 
Pyrosequencing: denaturating at 95ଇ for 5min, followed by 45 cycles at 95ଇ 
for 30sec, at each optimal temperature for 30sec, at 72ଇ for 30sec and a final 
extension at 72ଇ for 5min. The PCR reaction (4μl) was confirmed by 
electrophoresis in a 2% Agarose gel and visualized by ethidium bromide 
staining.  
ssDNA template was prepared from 16μl biotinylated PCR product using 
streptavidin Sepharose® HP beads (Amersham Biosciences, Sweden) 
following the PSQ 96 sample preparation guide using multichannel pipets.   
G
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Fifteen picomoles of the respective sequencing primer sere added for 
analysis. Sequencing was performed on a PyroMark ID system with the Pyro 
Gold reagents kit (Biotage, USA) according to the manufacturer’s instruction 
without further optimization. The methylation percentage was calculated by 
the average of the degree of methylation at 3 to 7 CpG sites formulated in 
pyrosequencing. 
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Data Analysis and Statistics  
Pyrosequencing presents methylation as a continous value. The Methylation 
index (MtI) at each gene promoter, and for each sample, was calculated as the 
average value of mC/(mC+C) for all examined CpG in the gene. The 
methylation status of CpG was analyzed as categorical variable (negative, MtI 
< 5%; positive, MtI>5%). All clinicopathologic variables, except age and 
tumor size, were used as categorical variables. Differences in continuous 
variables between 2 groups were evaluated by the Student t test, and 
differences in categorical variable were evaluated by the chi-square test. 
Kaplan-Meier method was used to calculate and display disease free survival 
curve, and the log-rank test was performed to determine differences among all 
groups. The Cox proportional hazards regression method was used to 
determine independent prognostic factors. P <0.05 was considered statistically 
significant.  
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III. RESULTS 
Cliniopathologic characteristics  
We studied 65 patients selected based on sample availability. Mean age was 
59.3 (± 8.8 years) and consisted of 45 men and 20 women. Of the 65 patients, 
9 underwent segmental resection of bile duct, 16 underwent 
pancreaticoduodenectomy and 40 underwent pylorus preserving 
pancreaticoduodenectomy. All patients underwent dissection of the lymph 
nodes in the hepatoduodenal ligament, common hepatic artery, and celiac axis. 
All patients were not treated with postoperative adjuvant chemotherapy.  
 
Gene specific Methylation Analysis   
Pyrosequencing data was successfully generated in 100% of tested samples 
for P16, 100% for DAPK, 95% for E-cadherin. We consider low level 
methylation (0-5%) to represent background ‘noise’ with questionable 
significance. The significant methylation frequencies (MtI > 5%) of the 3 
gene analyzed were 17% for P16, 54% for DAPK, 60% for E-cadherin. 
 
Analysis of Clinicopathologic features and Epigenetic information  
The clinicopathogic and molecular features of the 2 group are summarized in 
Table 2.  
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P16 and DAPK MtI status correlated with perineural invasion and tumor 
depth, respectively. But, patient age and sex, as well as tumor size, histologic 
grade and lymph node metastasis were not correlated with gene promoter 
methylation status.  
 
Disease free survival (DFS) and Overall Survival and Epigenetic 
Alterations 
The association of gene methylation with DFS (disease free survival) is 
evaluated using the Kaplan-Meier method and log-rank test. Table 3 shows 
unvariate analysis that included known clinicopathologic characteristics and 
other potential molecular biomarkers. In univariate analysis, depth of invasion, 
infiltrating formation tumor status had statistically significant factors as poor 
prognostic factors for DFS. (Table 3).  
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Table 3 Univariate prognostic factors of Disease Free Survival and overall 
survival  
 
DFS Overall Survival 
1 yr 3 yr p-value 3 yr 5 yr p-value 
Age 
≤ 60 yr 
> 60yr 
 
68.9 
75.9 
 
48.5 
41.8 
0.923 
 
54.5 
51.7 
 
45.5 
48.0 
0.766 
Sex 
M 
F 
 
69.1 
78.9 
 
42.6 
51.0 
0.888 
 
46.5 
73.7 
 
46.5 
45.1 
0.843 
OP  name  
Segmental 
PD/PPPD 
 
55.6 
75.0 
 
33.3 
41.6 
0.183 
 
44.4 
56.6 
 
44.4 
49.1 
0.944 
Tumor gross 
Nodular 
Infiltrating 
 
72.9 
66.7 
 
44.4 
0.0 
0.043 
 
57.1 
33.3 
 
53.6 
0.0 
0.003 
Tumor size 
≤ 15 mm 
> 15mm 
 
75.0 
68.2 
 
31.3 
48.7 
0.407 
 
56.3 
51.7 
 
37.5 
51.7 
0.303 
Histologic grade 
Well diff 
Mod/poor diff 
 
92.9 
66.2 
 
51.1 
43.2 
0.167 
 
57.1 
54.2 
 
57.1 
45.9 
0.703 
Depth of 
invasion 
T1/T2 
T3/T4 
 
 
 
83.5 
61.3 
 
 
54.1 
27.5 
0.034 
 
 
64.5 
45.2 
 
 
54.8 
41.9 
0.565 
G
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Lymph node 
metastais 
Negative 
Positive 
 
 
77.8 
63.9 
 
 
54.2 
32.1 
0.110 
 
 
66.7 
38.5 
 
 
66.7 
23.1 
0.001 
Perineural 
invasion 
No 
Yes 
 
 
69.0 
75.2 
 
 
51.1 
39.4 
0.559 
 
 
55.2 
54.6 
 
 
51.7 
45.5 
0.545 
P16 
Unmethylation 
Methylation 
 
74.5 
60.5 
 
44.7 
20.2 
0.107 
 
60.8 
27.3 
 
54.9 
18.2 
0.032 
DAPK 
Unmethylation 
Methylation 
 
71.7 
72.7 
 
37.2 
50.6 
0.607 
 
48.3 
60.7 
 
44.8 
51.6 
0.757 
E-cadherin 
Unmethylation 
Methylation 
 
63.6 
78.0 
 
39.7 
53.3 
0.522 
 
54.5 
56.8 
 
45.4 
51.4 
0.826 
 
 
In multivariate analysis, depth of invasion and infiltrating formation tumor 
status were identified as an independent prognostic factors for disease free 
survival. (Table 4). 
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Table 4. Mutivariate Cox Regression analysis of prognostic factors of Disease 
Free Survival   
Variables p-value Odd ratio 
Confidence interval (95%) 
Lower Upper 
Infiltrating formation tumor  0.029 2.980 1.119 7.938 
Deep invasion of Tumor   0.025 2.167 1.100 4.268 
 
 
In 65 patients, the 3-year and 5-year overall survival was 54.9% and 48.4%, 
respectively. In univariate analysis, infiltrating formation tumor, presence of 
lymph node metastasis, and P16 methylation status had significantly factors 
as poor prognostic factors. (Table 3) In multivariate analysis, presence of 
lymph node metastasis and P16 methylation status were identified as an 
independent prognostic factors for overall survival. (Table 5)  
 
Table 5. Mutivariate Cox Regression analysis of prognostic factors of Overall 
Survival  
Variables p-value Odd ratio 
Confidence interval (95%) 
Lower Upper 
Presence of lymph node  0.004 2.789 1.398 5.566 
Hypermethylation of P16 0.025 2.485 1.120 5.516 
G
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In patient with unmethylated of P16, the 3- and 5-year survival rates were 
60.8 % and 54.9 %, respectively. In patients with a hypermethylated of P16, 
the 3- and 5-year survival rates were 27.3 % and 0.0 %, respectively (Fig 1)  
 
 
 
Fig 1. Survival rates according to hypermethlyation of P16 
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IV. DISCUSSION 
Extrahepatic bile duct cancer is classified as proximal, middle, or distal bile 
duct cancer according to the anatomical location of the tumor in the biliary 
tree. As a result of differences in anatomy of the bile duct and consideration of 
local factors that relate to respectability, extrahepatic bile duct cancers have 
been divided into perihilar and distal bile duct cancers and separated in 
perihilar and distal group and separate staging classification according to 7th 
edition of TNM stage. And gallbladder carcinoma is also considered in some 
series to represent a sub-type of bile duct cancer. But we excluded proximal 
bile duct cancer and gallbladder cancer in this study.  
Pyrosequencing is a sequencing-by-synthesis method that allows accurate 
quantitative assessment of DNA methylation at CpG sites with high resolution. 
Pyrosequencing is more efficient and less expensive than combined bisulfite 
restriction analysis and is more reliable and accurate than a primer extension 
approach.8,9 In this study, we have first used pyrosequencing to determine the 
methylation profile of mid/distal bile duct cancer in a quantitative manner and 
could successfully analyze nearly 100% for pyrosequencing reaction.  
Tumorigenesis is a multistep process in which defects in various cancer 
genes accumulate. We reviewed the results of published studies looking at 
molecular biomarkers and their prognostic significance in bile duct cancer to 
select molecular markers. The PubMed was searched using the following 
keywords in varying combinations in order to identify published works in 
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English language to December 2010: bile duct cancer, prognosis, biomarkers 
and molecular markers. As the results, we selected putative oncogenes that 
had been previously identified in bile duct cancer.  
The percentage of tumors with methylated gene promoters was 54% for 
DAPK and 60% for E-cadherin. The high methylation frequency presented for 
CpG islands at DAPK and E-cadherin suggests that many signaling pathways 
could be involved in the development and progression of mid/distal bile duct 
cancer. However, association of methylated DAPK and E-cadherin with 
patient clinicopathological data does not supports their role in tumor 
progression. There have some reports to date that hypermethylated DAPK was 
associated with poor prognosis in EBD cancer. But, these studies contains 
with gallbladder cancer and ampulla of vater cancer.10,11 
Rate of hypermethylation of P16InK4a in bile duct cancer was reported to be 
18-83%,12 while that in this study was 17%, lower than that in previous 
studies.10,13 This results may be due to the diversity of criteria on the selection 
of the subjects in the previous studies.  
P16InK4a inactivation has been reported to be an early and critical event in 
tumor progression in some types of tumors.14,15 A recent study has shown that 
the re-expression of P16 inhibits lymphangiogenesis and lymphatic metastasis 
of pancreatic cancer in the mouse model.16 We observed that promoter 
hypermethylation of the P16InK4a was associated with perineural invasion 
which was early event in bile duct cancer.17 This result on P16InK4a 
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hypermethylation suggests that P16 hypermethylation may represent an early 
alteration preceding the phenotypic alteration in the mid/distal bile duct 
cancer.  
Few prior studies have investigated bile duct cancer methylation status and 
prognosis. We found that P16InK4a promoter hypermethylation was associated 
with a poor prognosis, thus indicating that it could be an important biomarker 
in patients with mid/distal bile duct cancer. Some reports have demonstrated 
that P16InK4a promoter methylation is associtated with prognostic biomarkers 
in many cancers.18-20 It remains unclear how P16 methylation affects 
prognosis in this studies. Therefore, further studies will be needed.  
There some limitations in this study. First, the frequency of 
hypermethylation of P16 is relative small. Thus some subgroup analyses are 
based on small number of patients, which are relected in the wide confidence 
intervals. These results should be interpreted carefully. Second, our proportion 
of our study participants are asian people with mid/distal bile duct cancer, and 
thus our results are not generalized to other race.  
Nonetheless, we have some advantage include a homogenous and large 
volume of patients diagnosed with mid/distal bile duct cancer. This approach 
allows for greater generalizability and higher sensitivity, since multiple factors 
were taken into consideration in examining the associations with survival.  
Moreover, there are few epigenetic studies that have reported on the 
prognostic value of gene promoter methylation status in bile duct cancer.  
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V. CONCLUSION 
In conclusions, this candidate-base study describes the hypermethylation profile of 
three oncogenes in mid/distal bile duct cancer to elucidate the clinical implication of 
aberrant DNA hypermethylation. P16InK4a hypermethylation can predict overall 
survival in curative resected mid/distal bile duct cancer. Further study is warranted to 
validate the use of high frequency methylated genes as potential biomarkers for 
prognosis in mid/distal bile duct cancer. Classification of mid/distal bile duct cancer 
by both genetic and epigenetic profiles may improve the capability of predicting 
prognosis and of applying tailored therapy in mid/distal cancer. Therefore, further 
research with large number of patients is needed to investigate the 
pathophysiology and possible role of DNA hypermethylation in patients with 
mid/distal bile duct cancer. 
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ABSTRACT(IN KOREAN) 
P16 and MGMT hypermethylation predicts surgical outcomes  
in curative resected mid/distal bile duct cancer. 
 
<㰖☚ᾦ㑮 㥺 ☯ ㎃> 
 
㡆㎎╖䞯ᾦ ╖䞯㤦 㦮䞯ὒ 
 
⹫ 㭖 ㎇ 
 
 
㡆ῂ ⳿㩗 : 㤆Ⰲ⋮⧒㠦㍲ ╊☚㞪㦖 ㏢䢪₆ 㞪㭧 㥚㞪, Ṛ㞪, ╖
㧻㞪 ┺㦢㦒⪲ 䦪䞲 㞪㧊Ⳇ, ╊☚㞪㦮 㡞䤚⓪ ⰺ㤆 ⿞⨟䞲 ộ㦒⪲ 
⽊ἶ ♮Ⳇ, 㡞䤚㠦 ὖ⩾♲ 㧎㧦⪲㍲ 㰚┾ ╏㔲㦮 ⼧₆, 㞪㎎䙂㦮 ⿚
䢪☚ ⹥ 㫆㰗㥶䡫㧊 㭧㣪䞮┺. ⁎⩒㠦☚ ⿞ῂ䞮ἶ, 㰚┾ ╏㔲㦮 ⼧
₆㢖⓪ ┺⯎ 䢮㧦✺㦮 㡞䤚⯒ ✲ⶒ㰖 㞠Ợ ἓ䠮䞮㡂, 䡚㨂 Ⱔ㧊 㧊
㣿♮⓪ TNM⿚⮮⻫ Ⱒ㧊 㞚┢ 㿪Ṗ㩗㧎 㡞䤚 㧎㧦㦮 䞚㣪㎇㧊 㩲₆
♲┺. ➆⧒㍲ ⽎ 㡆ῂ⓪ 㞪㦮 䤚㎇㩗 ⼖䢪㧎 䝚⪲⳾䎆 CpG island ὒ
Ⲫ䕎䢪 㡂⿖Ṗ ╊☚㞪㠦㍲ 䢮㧦㦮 㡞䤚⯒ 㡞䁷䞶 㑮 㧞⓪ 㰚┾㩗 
䚲㰖㧦⪲㍲㦮 㧚㌗㩗 㥶㣿㎇㠦 ╖䟊 ⿚㍳䟊 ⽊ἶ㧦 䞲┺.  
╖㌗ ⹥ ⹿⻫: 2000⎚ 1㤪⿖䎆 2006⎚ 12㤪₢㰖 ╊☚㦮 㤦⹲㎇ 
㞛㎇ 㫛㟧㦒⪲ 㡆㎎╖䞯ᾦ 㦮ὒ╖䞯 ㎎ぢ⧖㓺 ⼧㤦㠦 㧛㤦䞮㡂 ⁒
䂮 㑮㑶㦚 ⹱㦖 䢮㧦 㭧 㫆㰗㦮 ⽊ὖ㌗䌲Ṗ 㟧䢎䞮ἶ 㦮ⶊ ₆⪳ὒ 
G
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㑮㑶 䤚 ㌳㫊 㡂⿖㦮 㿪㩗㧊 Ṗ⓻䞲 65ⳛ㦚 ╖㌗㦒⪲ 䞮㡖┺. ṗ 㥶
㩚㧦㦮 CpG island㦮 ὒⲪ䕎䢪⯒ pyroswquencing㦒⪲ 㩫⨟䢪䞮㡂 ₆
㫊㦮 㡞䤚 㧎㧦㢖㦮 ゚ᾦ䞮㡖┺. 
ἆὒ: 㩚㼊 65ⳛ ╖㌗ 䢮㧦㠦㍲ CpG island㦮 ὒⲪ䕎䢪⓪ P16㠦㍲⓪ 
17%, DAPK㠦㍲⓪ 54%, E-cadherin㠦㍲⓪ 60%㧊㠞┺., P16㦮 ὒⲪ䕎䢪
⓪ 㔶ἓ㩞 䂾㥺, DAPK㦮 ὒⲪ䕎䢪 㩫☚⓪ 㫛㟧㦮 䂾㥺 㩫☚㢖 䐋Ἒ
䞯㩗 㡆ὖ㎇㧊 㧞㠞┺. P16㦮 ὒⲪ䕎䢪 㩫☚㠦 ➆⯎ 5⎚ ㌳㫊㥾㦖 
ὒⲪ䕎䢪ῆ㧊 0%, ゚Ⲫ䕎䢪ῆ㧊 54.9%⪲ 䐋Ἒ䞯㩗㦒⪲ 㥶㦮䞲 㹾㧊
Ṗ 㧞㠞㦒Ⳇ, ┺⼖⨟ ⿚㍳㠦㍲☚ 㭧㣪䞲 㡞䤚㧎㧦⪲ 䕦ⳛ♮㠞┺. 
ἆ⪶:, P16㦮 ὒⲪ䕎䢪⯒ ⽊㧎 䢮㧦✺㧊 ▪㤇 ⋮㊲ 㡞䤚⯒ ⽊㡂 
P16㦮 Ⲫ䕎䢪 㡂⿖Ṗ ╊☚㦮 㤦⹲㎇ 㞛㎇ 㫛㟧㠦㍲ 㡞䤚 㧎㧦⪲㍲
㦮 ₆⓻㦖 䞶 㑮 㧞┺ἶ 㡂Ỿ㰚┺.  
 
 
 
 
 
 
 
 
 
 
------------------------------------------------------------------------------------ 
䟋㕂♮⓪ Ⱖ : ╊☚㞪, CpG island, ὒⲪ䕆䢪, ㌳㫊⮶, P16  
